1. CMU Intellectual Repository

Browsing by Author Yi Long Wu

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 2 to 9 of 9 < previous 
Issue DateTitleAuthor(s)
15-Jul-2015Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapyTony Mok; Yi Long Wu; Jin Soo Lee; Chong Jen Yu; Virote Sriuranpong; Jennifer Sandoval-Tan; Guia Ladrera; Sumitra Thongprasert; Vichien Srimuninnimit; Meilin Liao; Yunzhong Zhu; Caicun Zhou; Fatima Fuerte; Benjamin Margono; Wei Wen; Julie Tsai; Matt Truman; Barbara Klughammer; David S. Shames; Lin Wu
1-Feb-2017Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLCYi Long Wu; Nagahiro Saijo; Sumitra Thongprasert; J. C.H. Yang; Baohui Han; Benjamin Margono; Busayamas Chewaskulyong; Patrapim Sunpaweravong; Yuichiro Ohe; Yukito Ichinose; Jin Ji Yang; Tony S.K. Mok; Helen Young; Vincent Haddad; Yuri Rukazenkov; Masahiro Fukuoka
3-Sep-2009Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S. Mok; Yi Long Wu; Sumitra Thongprasert; Chih Hsin Yang; Da Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L. Duffield; Claire L. Watkins; Alison A. Armour; Masahiro Fukuoka
1-Jun-2017Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalChee Khoon Lee; Lucy Davies; Yi Long Wu; Tetsuya Mitsudomi; Akira Inoue; Rafael Rosell; Caicun Zhou; Kazuhiko Nakagawa; Sumitra Thongprasert; Masahiro Fukuoka; Sally Lord; Ian Marschner; Yu Kang Tu; Richard J. Gralla; Val Gebski; Tony Mok; James Chih Hsin Yang
1-Jan-2011Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)Sumitra Thongprasert; Emma Duffield; Nagahiro Saijo; Yi Long Wu; James Chih Hsin Yang; Da Tong Chu; Meilin Liao; Yuh Min Chen; Han Pin Kuo; Shunichi Negoro; Kwok Chi Lam; Alison Armour; Patrick Magill; Masahiro Fukuoka
1-Sep-2010Lung cancer working group reportNagahiro Saijo; Masahiro Fukuoka; Sumitra Thongprasert; Yukito Ichinose; Tetsuya Mitsudomi; Tony Shu Kam Mok; Yuichiro Ohe; Keunchil Park; Yi Long Wu
1-Aug-2016Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancerTony Mok; Guia Ladrera; Vichien Srimuninnimit; Virote Sriuranpong; Chong Jen Yu; Sumitra Thongprasert; Jennifer Sandoval-Tan; Jin Soo Lee; Fatima Fuerte; David S. Shames; Barbara Klughammer; Matt Truman; Pablo Perez-Moreno; Yi Long Wu
1-Aug-2013Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS studyYi Long Wu; Masahiro Fukuoka; Tony S.K. Mok; Nagahiro Saijo; Sumitra Thongprasert; James C.H. Yang; Da Tong Chu; Jin Ji Yang; Yuri Rukazenkov
Showing results 2 to 9 of 9 < previous